AGIOS PHARMACEUTICALS, INC. (AGIO)
D
Pipeline Grade
Financial Position (from SEC Filings)
$113.6M
Cash & Equivalents
$118.9M
Quarterly Burn Rate
3 mo
Est. Cash Runway
$2,452M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2027-03-01 | Phase2 Readout | — |
Active Clinical Trials (13)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05777993 | A Study to Provide Continued Access to Mitapivat for Participants Who Previously Completed an Agios-Sponsored Mitapivat ... | PHASE4 | Enrolling By Invitation | 6 |
| NCT03481738 | Pyruvate Kinase Deficiency Global Longitudinal Registry | OTHER | Active Not Recruiting | 500 |
| NCT04770753 | A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Th... | PHASE3 | Active Not Recruiting | 194 |
| NCT05144256 | A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD)... | PHASE3 | Active Not Recruiting | 49 |
| NCT05175105 | A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD)... | PHASE3 | Active Not Recruiting | 30 |
| NCT04770779 | A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalas... | PHASE3 | Active Not Recruiting | 258 |
| NCT07055243 | To Assess Safety of Mitapivat and Provide Proof of Concept of the Efficacy of the Drug in Patients With RBC Membranopath... | PHASE2 | Recruiting | 9 |
| NCT05490446 | A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS) | PHASE2 | Active Not Recruiting | 87 |
| NCT03692052 | A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With N... | PHASE2 | Active Not Recruiting | 20 |
| NCT04278781 | AG-120 in People With IDH1 Mutant Chondrosarcoma | PHASE2 | Active Not Recruiting | 6 |
| NCT06924970 | A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD) | PHASE2 | Active Not Recruiting | 59 |
| NCT07241234 | A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With Phenylketonu... | PHASE1 | Recruiting | 20 |
| NCT07075640 | A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the ... | PHASE1 | Active Not Recruiting | 24 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.